Increased risk of fracture in patients receiving solid organ transplants.

The success of organ transplantation is related to advances in immunosuppressive therapy. These medications are associated with medical complications including bone damage. The objective of this study was to estimate and compare age, gender-specific fracture incidence between transplant recipients, and a large sample representative of the civilian noninstitutionalized United States population using the 1994 National Health Interview Survey (NHIS). This was a cohort study set in tertiary care centers. Five hundred and thirty-nine individuals who received abdominal organ and 61 heart transplants surviving at least 30 days at our institution from 1986 to 1996 were included in the study. Incident fractures were ascertained by mail, in-person interview, telephone survey, or medical record review. All fractures were verified. Organ-, age-, and gender-specific fracture numbers and rates and person-years of observation, were calculated for the transplant patients. Weighted age- and gender-specific fracture rates from the 1994 NHIS were applied to the number of person-years of observation for each organ-specific age and gender category of transplant patients to generate an expected number of fractures. The ratio of observed to expected number of fractures was used to compare fracture experience of transplant patients to that of the national sample from the 1994 NHIS. Fifty-six of 600 (9.3%) patients had at least one fracture following 1221 person-years of observation. The sites of initial symptomatic fracture were as follows: foot (n = 22), arm (n = 8), leg (n = 7), ribs (n = 6), hip (n = 4), spine (n = 3), fingers (n = 3), pelvis (n = 2), and wrist (n = 1). Fracture incidence was 13 times higher than expected in male heart recipients age 45-64 years; nearly 5 times higher in male kidney recipients age 25-44 and age 45-64 years; and 18 times and 34 times higher in female kidney recipients age 25-44 years and 45-64 years compared with NHIS data. We have shown an increased incidence of fractures and estimated the magnitude of this problem in patients undergoing solid organ transplantation. Our work defines the need for a long-term prospective study of fracture risk in these patients.

Immediate hemodynamic effects of thrombolytic therapy on the ischemic myocardium.

Thrombolytic agents are used to restore coronary artery perfusion and limit the size of a myocardial infarction. The systemic effects of these drugs, streptokinase (SK), urokinase (UK), and recombinant tissue plasminogen activator (rtPA), have been studied extensively. Although their effects on rheology and late myocardial performance have been well-documented to date, there have not been any studies evaluating the acute hemodynamic consequences of thrombolytics immediately after administration. In this report we use an isolated Langendorf rodent heart preparation to evaluate the acute hemodynamic effects of thrombolytic therapy on both the normal and the ischemic myocardium. We quantified performance by documenting cardiac output, coronary blood flow, and blood pressure. Although each thrombolytic agent significantly transiently impairs cardiac performance, differences in effect between the agents were statistically insignificant. This was also the case with both the normal as well as the ischemic myocardium. The results of this study would not support favoring the use of one of these agents over the other with regards to primary myocardial performance.

Modulation of alloreactivity in transplant recipients by phenotypic manipulation of donor endothelium.

Phenotypic manipulation of allograft endothelium to reduce immunogenicity would have a significant impact on transplantation. In this study we have demonstrated that random seeding of a heart allograft with endothelium, of host origin, not only promotes long-term survival, but reduces the requirement for pharmacologic immunosuppression. We propose that this simple technology could easily be extrapolated to the clinical arena where hypothermia and preservation solutions have allowed allografts to remain ex vivo for extended periods.

Primary cutaneous aspergillosis in a heart transplant recipient treated with surgical excision and oral itraconazole.

A 24-year-old man underwent orthotopic heart transplantation for treatment of end-stage complex congenital heart disease. Six weeks postoperatively, five erythematous skin lesions developed on the patient's right forearm. Punch biopsy revealed Aspergillus. Despite extensive testing, no other potential primary site was located. Because of concern of dissemination, the patient was treated with a combination of local debridement and systemic antifungal therapy with itraconazole. He is presently without signs or symptoms of recurrent disease.

Right lower lobectomy for pulmonary infarction before orthotopic heart transplantation.

A 39-year-old potential heart transplant recipient had a right lower lobe infiltrate and on pulmonary angiography was found to have an embolous to the common basilar artery. This was successfully managed by a right lower lobectomy, after aggressive medical management failed. The patient was treated postoperatively with antibiotics and subsequently underwent orthotopic heart transplantation. At 1 year after transplant the patient has no evidence of cardiac or pulmonary insufficiency.

Systemic and local saphenous vein graft thrombolysis using a tissue plasminogen activator.

Many studies are currently evaluating the potential role of thrombolytic therapy in patients with ischemic syndromes who have undergone previous coronary artery bypass grafting. Limited experience has been published regarding the use of local urokinase and streptokinase infusions and the use of systemic recombinant tissue-type plasminogen activator as thrombolytic agents in patients with previous coronary artery bypass surgery. To date, however, there has been no published experience regarding the use of recombinant tissue-type plasminogen activator (rt-PA) either systemically or locally in the post-bypass patient where angiographic demonstration of aortocoronary saphenous vein graft obstruction was available pre- and post-therapy. Similarly there has been no previous report of the use of rt-PA infused locally to recanalize an occluded aortocoronary saphenous vein graft. This report describes successful thrombolysis and subsequent balloon angioplasty of saphenous vein grafts with angiographically documented thrombus using systemic and local rt-PA infusion.

First use of a 5 French diagnostic catheter as a guiding catheter for percutaneous transluminal coronary angioplasty.

We report the first use of a 5 French thin-wall, large-lumen diagnostic angiographic catheter as a guiding catheter for emergency angioplasty with an angioplasty balloon on a wire (PROBE) for patients with acute circumflex coronary occlusion and hemodynamic compromise.